EPISODE · Jun 24, 2025 · 12 MIN
ASCO 2025 Plenary: SERENA-6
from Two Onc Docs
This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer.We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.
NOW PLAYING
ASCO 2025 Plenary: SERENA-6
No transcript for this episode yet
Similar Episodes
Feb 4, 2026 ·72m
Oct 22, 2025 ·38m
Oct 15, 2025 ·30m